Actively Recruiting
FAPI PET/CT in Various FAP-Related Disease Patients
Led by Tianjin Medical University · Updated on 2025-02-11
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
T
Tianjin Medical University
Lead Sponsor
T
Tianjin Medical University General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the usefulness of 68Ga/18F-FAPI PET/CT scans for diagnosing primary and metastatic lesions in patients with various FAP-related diseases. This observational study evaluates how well this imaging method detects tumors by measuring uptake values and calculating diagnostic accuracy, including sensitivity and specificity. Participants receive a single intravenous injection of 68Ga/18F-FAPI followed by PET/CT imaging within a specified time frame. The study measures the maximum standardized uptake value (SUVmax) of lesions. This approach is used for either initial assessment or detection of recurrence in malignant tumors. During the study, researchers assess lesion uptake and diagnostic efficacy within 30 days. Patients undergo PET/CT imaging and provide informed consent. The study monitors diagnostic outcomes to determine how effectively 68Ga/18F-FAPI PET/CT identifies tumor lesions in FAP-related diseases. Participation involves one imaging procedure and follow-up assessments within a month.
CONDITIONS
Brief Title
FAPI PET/CT in Various FAP-Related Disease Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Patients with suspected, newly diagnosed, or previously treated malignant tumors
- Patients scheduled for FAPI PET/CT scan
- Ability to provide informed consent and assent according to ethics guidelines
You will not qualify if you...
- Patients with non-malignant lesions
- Patients who are pregnant
- Inability or unwillingness to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive a single intravenous injection of 68Ga/18F-FAPI and undergo PET/CT imaging for initial assessment or recurrence detection of FAP-related disease.
1 visit (in-person)
Duration - Up to 30 days
Participants are monitored for up to 30 days to assess standardized uptake values and diagnostic efficacy of the PET/CT scan.
Follow-up assessments as needed
Trial Site Locations
Total: 1 location
1
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China, 300052
Actively Recruiting
Research Team
H
Haonan Yu, MD
S
Shaobo Yao, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here